Lupin Limited Announces Launch of Mirabegron Extended-Release Tablets, 25 Mg, in the United States, After Having Received an Approval from the United States Food and Drug Administration

Lupin Limited (Lupin) announced the launch of Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA). Mirabegron Extended-Release Tablets, 25 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 25 mg of Astellas Pharma Global Development Inc. Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of USD 1,019 million in the U.S. (IQVIA MAT February 2024).